Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322896 | 0.85 | TACR1 (0.60) | TACR1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL9322906 | 0.85 | TACR1 (0.60) | TACR1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL9322903 | 0.85 | TACR1 (0.60) | TACR1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL9767363 | 0.84 | TACR1 (0.53) | TACR1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL9323198 | 0.83 | TACR1 (0.60) | TACR1 | |
| SCHEMBL9322808 | 0.83 | TACR1 (0.60) | TACR1 | |
| SCHEMBL9321890 | 0.82 | TACR1 (0.56) | TACR1 | |
| Hydrochloric Acid SCHEMBL9323145 | 0.82 | TACR1 (0.56) | TACR1 | |
| SCHEMBL9324189 | 0.80 | TACR1 (0.53) | TACR1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL28838840 | 0.79 | CHRNA7 (0.62) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299100-B1 | METHOD OF TREATING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIV ROCHESTER (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1551833-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2005-04-21 | — | — | US | disclosed |
| US-6861526-B2 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1299100-A4 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIV ROCHESTER (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040116704-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004035575-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | PFIZER PRODUCTS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030236237-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | GUTTUSO THOMAS J (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1299100-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | THE UNIVERSITY OF ROCHESTER (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020016283-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | UNIVERSITY OF ROCHESTER | 2002-02-07 | — | — | US | disclosed |
| WO-2001095904-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIVERSITY OF ROCHESTER (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | BCKDK, SRM, SKP1 | TACR1 1140/4885CHRNA7 835/4885CHRNB2 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.